In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin.

Robert M TaylorJames A KarlowskyMelanie R BaxterHeather J AdamAndrew WalktyPhilippe Lagacé-WiensGeorge G Zhanel

Published in: Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada (2021)

(MSSA) (MIC ≤0.25 μg/mL; 70 specimens) at their susceptible breakpoints. Conclusions: Lefamulin demonstrated potent in vitro activity against all respiratory isolates tested and may represent a significant advancement in empiric treatment options for CAP.

Keyphrases

respiratory tract
gram negative
antimicrobial resistance
genetic diversity
anti inflammatory
urinary tract infection
multidrug resistant